title: Countrywide management of pulmonary tuberculosis reverses increasing incidence.
abstract: OBJECTIVE
  To evaluate the impact of countrywide management of tuberculosis (TB) and the availability of second-line drugs (SLDs) on the notification rates of pulmonary TB (PTB) overall and of multidrug-resistant TB (MDR-TB), taking into account human immunodeficiency virus (HIV) co-infection and the national economy in Estonia.
  
  
  METHODS
  Retrospective analysis of notification rates and treatment outcomes of PTB and MDR-TB during 1998-2006.
  
  
  RESULTS
  The annual notification rates of both PTB and MDR-TB decreased significantly, by on average 3.3 (P = 0.007) and 1.7 (P = 0.008) cases per 100,000 population, respectively. The accelerating impact of SLD availability on the annual decline was significant for both PTB overall and MDR-TB (P = 0.003 and P = 0.025, respectively). During 1998-2006, an increase in TB-HIV co-infection (P = 0.009) significantly affected the notification rates of both PTB overall and MDR-TB (P < 0.001 and P < 0.001, respectively). The negative impact of TB-HIV co-infection was counterbalanced by the availability of SLDs, the decrease in the MDR-TB rate and the increase in gross domestic product (GDP) per capita, as confirmed by multivariate analysis.
  
  
  CONCLUSIONS
  Countrywide access to SLDs and the coordinated effect of programmatic conditions can, in parallel with increasing GDP, reverse the increasing notification rates of PTB and MDR-TB in the context of an HIV epidemic.
authors.affiliation: Lung Clinic, Tartu University Clinics, Tartu, Estonia. kaivink@kodu.ee
authors.forename: K
authors.initials: K
authors.lastname: Blöndal
authors.forename: P
authors.initials: P
authors.lastname: Viiklepp
authors.forename: P
authors.initials: P
authors.lastname: Blöndal
authors.forename: A
authors.initials: A
authors.lastname: Altraja
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D018563:Disease Notification / Q000706:statistics & numerical data; D004957:Estonia / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000453:epidemiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000995:Antitubercular Agents